These beautiful and often other-worldly photographs by pathologist Ed Uthman, MD, show both benign and malignant ovarian pathology.
These beautiful and often other-worldly photographs by pathologist Ed Uthman, MD, show both benign and malignant ovarian pathology.
Benign Ovarian Cyst
A benign 4.5 cm cyst of follicular origin.
Brenner Tumor of the Ovary
Two percent of all ovarian tumors are Brenner tumors, and they can be benign, proliferative, or malignant. This one was found in a patient with cervical carcinoma.
Fibroma of the Ovary
Though it’s the most common sex cord-stromal tumor, it is rare, comprising about 3% of benign tumors.
Mature Cystic Teratoma of Ovary
This benign, 4 cm mature cystic teratoma of the ovary was found incidentally at the time of Caesarean section. There were abundant neuroglia and even one neuron. Central nervous system tissue is very common in mature teratomas.
Mucinous Cystadenocarcinoma of the Ovary
This is a rare type of epithelial tumor. Studies indicate that many tumors initially diagnosed as primary tumors may, in fact, have metastasized from another site.
Ovarian Mucinous Cystadenoma
This 11 cm mucinous ovarian tumor had unusually rigid walls and an endocervical type lining.
Proliferating Mucinous Tumor of the Ovary
This solid 13 cm tumor was found in a 74 year-old woman. There was a microscopic metastasis in the other ovary, and the peritoneal washings were positive.
Serous LMP Tumor
An ovarian serous tumor of low malignant potential (S-LMP) or “borderline tumor” are distinct from both benign serous tumors and serous carcinoma. Most of these tumors are clinically benign, but sometimes recur and occasionally progress to low-grade serious carcinoma. Follow-up is important.
Normal Human Ovary with Fully Developed Corpus Luteum
This normal ovary was removed in the course of a hysterectomy for uterine disease. The bright yellow corpus luteum is fully developed, as it would be in the mid-luteal phase of the menstrual cycle following ovulation.
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More
Unifying radical hysterectomy classifications with the Querleu-Morrow
February 16th 2024Explore how the latest research underscores the efficacy of the 2017 Querleu-Morrow classification in defining radical hysterectomy extent, shedding light on surgical terminologies for cervical cancer management.
Read More